High-Quality Gene Editing Enzymes | Cas9, Cas12a, AccuBase

Empower Your Research with Precision DNA Enzymes

At KACTUS, we are dedicated to pushing the boundaries of gene editing technology. Our commitment to innovation and excellence drives us to develop and provide the highest quality gene editing enzymes, including Cas9, Cas12a, and AccuBase. These cutting-edge tools empower researchers and scientists to achieve precise and efficient gene modifications, paving the way for groundbreaking advancements in genomics, therapeutics, and beyond. Join us on our mission to transform the future of gene editing and unlock new possibilities in the life sciences.

Download Product Brochure:

View Now

AccuBase™: The Next Generation Base Editor

AccuBase™ is a cytosine base editor engineered by Base Therapeutics and manufactured for global sales by KACTUS. It creatively embeds a deaminase inside the Cas protein to prevent random binding of deaminase to non-target sites, significantly reducing off-target occurrence while still maintaining high editing efficiency. Using our protein engineering and expression platform, Structure Aided Multiplex Screening (SAMS™), KACTUS has successfully manufactured the DNA base editor. We've maximized the stability, purity, and activity of AccuBase™ by screening our AccuBase™ protein expression system, optimizing the purification process, and performing formulation development. AccuBase™ is a cytosine base editor which can convert a C•G base pair into a T•A base pair.

Learn More → View the brochure

GMP-Grade Research-Grade

AccuBase™ RNP was electroporated into activated primary T cells. According to flow cytometry, AccuBase™ can efficiently knock out PD, B2M, and TRAC proteins on the membrane of activated primary T cells at the protein level. For PD1 and B2M, the knockout efficiency exceeded 80%, while the knockout efficiency of TRAC reached 96%.

CRISPR Cas9 Protein: The classic CRISPR Workhorse

KACTUS has successfully developed a highly active GMP-grade Cas9 nuclease based on our Structure Aided Multiplex Screening (SAMS™) technology platform. Our Cas9 Nuclease is the wild-type sequence that has undergone codon optimization, nuclear localization signal (NLS) design, and optimization of E. coli expression and purication. Our GMP-Grade Cas9 Nuclease is available in long-term bulk supply with consistent batch activity, to ensure a smooth transition while scaling up your drug production from development to manufacturing.

GMP-Grade Research-Grade

Gene knockout efficiency was analyzed using three batches of KACTUS GMP-Grade Cas9. Knockout of BCL11A, BCL11A, and TRAC gene was analyzed for 293T, Jurkat, and T cells, respectively. The cells were electroporated with 75 pmol of Cas9 protein along with 225 pmol of sgRNA into three cell types. TIDE analysis was performed after three days of culture post-electroporation. Results show greater than 85% editing efficacy across all three cell types, comparable to industry leading supplier.

Cas12a: The Versatile Gene Editor

KACTUS provides a highly active AsCas12a nuclease. Different from Cas9 nuclease, AsCas12a targets T-rich sequences and forms 4-5 nucleotide protruding 5' sticky ends after cutting double-stranded DNA.

Our Cas12a enzyme is manufactured research-grade but can be moved to GMP-Grade production standards upon agreement.

Learn more about our GMP enzyme production or contact us to discuss your specific requirements.

Research-Grade